{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:23:08Z","timestamp":1793262188336,"version":"4.5.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jcf.2024.05.008","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T08:21:32Z","timestamp":1716279692000},"page":"1024-1026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical and radiological improvement of cavitary Mycobacteroides abscessus disease in cystic fibrosis following initiation of elexacaftor\/tezacaftor\/ivacaftor"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1403-6309","authenticated-orcid":false,"given":"Roderick","family":"Gavey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0092-8216","authenticated-orcid":false,"given":"James","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jcf.2024.05.008_bib0001","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/cells11071243","article-title":"CFTR modulator therapies: potential impact on airway infections in cystic fibrosis","volume":"11","author":"Saluzzo","year":"2022","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.jcf.2024.05.008_bib0002","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jcf.2009.12.001","article-title":"Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis","volume":"9","author":"Esther","year":"2010","journal-title":"J Cystic Fibrosis"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2024.05.008_bib0003","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-207360","article-title":"US Cystic fibrosis foundation and European cystic fibrosis society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis","volume":"71","author":"Floto","year":"2016","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.jcf.2024.05.008_bib0004","doi-asserted-by":"crossref","first-page":"00724","DOI":"10.1183\/23120541.00724-2021","article-title":"CFTR modulator use and risk of nontuberculous mycobacteria positivity in cystic fibrosis, 2011\u20132018","volume":"8","author":"Ricotta","year":"2022","journal-title":"ERJ Open Res"},{"issue":"1","key":"10.1016\/j.jcf.2024.05.008_bib0005","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jcf.2023.03.021","article-title":"Eradication of Mycobacterium abscessus infection in cystic fibrosis with initiation of Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"23","author":"McParland","year":"2024","journal-title":"J Cys Fibrosis"},{"issue":"4","key":"10.1016\/j.jcf.2024.05.008_bib0006","first-page":"396","article-title":"CFTR Modulator Therapy in an Individual With Cystic Fibrosis Caused by a N1303K CFTR Variant and Infected With Mycobacterium abscessus","volume":"27","author":"Elson","year":"2022","journal-title":"J Pediat Pharmacol Therapeut"},{"issue":"1","key":"10.1016\/j.jcf.2024.05.008_bib0007","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jcf.2023.05.003","article-title":"Eradication of Nontuberculous Mycobacteria in people with cystic fibrosis treated with Elexacaftor\/Tezacaftor\/Ivacaftor: a multicenter cohort study","volume":"23","author":"Wiesel","year":"2024","journal-title":"J Cys Fibrosis"},{"issue":"7","key":"10.1016\/j.jcf.2024.05.008_bib0008","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.3390\/ijms23073513","article-title":"The effect of CFTR modulators on airway infection in cystic fibrosis","volume":"23","author":"Harvey","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.jcf.2024.05.008_bib0009","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00216-2023","article-title":"The effects of Elexacaftor\/Tezacaftor\/Ivacaftor beyond the epithelium: spurring macrophages to fight infections","volume":"61","author":"Bruscia","year":"2023","journal-title":"Eur Respir J"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:13:14Z","timestamp":1788246794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324000717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1569199324000717"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.05.008","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and radiological improvement of cavitary Mycobacteroides abscessus disease in cystic fibrosis following initiation of elexacaftor\/tezacaftor\/ivacaftor","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}